Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL812036 | 0.84 | PDE10A (0.48) | ALDH1A1ALOX15TSHRPDE10ACYP1A2 | |
| SCHEMBL1586433 | 0.84 | ALDH1A1 (0.47) | ALDH1A1ALOX15TSHRPDE10AMEN1 | |
| SCHEMBL1703281 | 0.77 | LMNA (0.45) | ALDH1A1ALOX15TSHRCYP1A2MEN1 | |
| SCHEMBL1830615 | 0.77 | PDE10A (0.37) | PDE10A | |
| SCHEMBL6462055 | 0.74 | MEN1 (0.39) | ALDH1A1ALOX15TSHRMEN1KMT2A | |
| SCHEMBL439985 | 0.73 | PDE10A (0.39) | PDE10A | |
| SCHEMBL8382893 | 0.72 | ALDH1A1 (0.30) | ALDH1A1ALOX15TSHR | |
| SCHEMBL23443915 | 0.72 | ALDH1A1 (0.35) | ALDH1A1ALOX15TSHR | |
| SCHEMBL10043017 | 0.72 | ALDH1A1 (0.35) | ALDH1A1ALOX15TSHR | |
| SCHEMBL10603143 | 0.72 | PDE10A (0.52) | ALDH1A1ALOX15TSHRPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132147-A1 | BAX INHIBITORS AND USES THEREOF | CASE WESTERN RESERVE UNIV (US) | 2026-05-14 | — | — | US | disclosed |
| US-12552790-B2 | Positive modulators of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2026-02-17 | — | — | US | disclosed |
| US-20260035366-A1 | POSITIVE MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | UNIV VANDERBILT (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260034127-A1 | TREATMENT OF GVHD | KADMON CORP LLC (FR) | 2026-02-05 | — | — | US | disclosed |
| US-12479857-B2 | Bax inhibitors and uses thereof | CASE WESTERN RESERVE UNIVERSITY (US) | 2025-11-25 | — | — | US | disclosed |
| US-12448380-B2 | Positive modulators of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2025-10-21 | — | — | US | disclosed |
| US-20250230155-A1 | 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY | 2025-07-17 | — | — | US | disclosed |
| US-12344608-B2 | Positive modulators of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2025-07-01 | — | — | US | disclosed |
| US-20250136600-A1 | POSITIVE MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2025-05-01 | — | — | US | disclosed |
| US-20250122198-A1 | POSITIVE MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2025-04-17 | — | — | US | disclosed |
| US-6545008-B1 | Inhibitory activity against gastric acid secretion | YUHAN CORPORATION (KR) | 2003-04-08 | — | — | US | disclosed |
| US-6352993-B1 | ANTIULCER AGENTS | YUHAN CORPORATION (KR) | 2002-03-05 | — | — | US | disclosed |
| CN-1326453-A | Novel poyrimidine derivatives and process for preparation thereof | YUHAN CORP (KR) | 2001-12-12 | — | — | CN | disclosed |
| EP-1131312-A1 | NOVEL PYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION, LTD. (KR) | 2001-09-12 | — | — | EP | disclosed |
| WO-2000029403-A1 | NOVEL PYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2000-05-25 | — | — | WO | disclosed |
| US-5750531-A | ANTISECRETORY AGENTS FOR THE TREATMENT OF PEPTIC ULCER | YUHAN CORPORATION (KR) | 1998-05-12 | — | — | US | disclosed |
| EP-0775120-A1 | NOVEL PYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | Yuhan Corporation (KR) | 1997-05-28 | — | — | EP | disclosed |
| WO-1996005177-A1 | NOVEL PYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 1996-02-22 | — | — | WO | disclosed |
| US-4980350-A | Piperazinylalkylpyrimidines as hypoglycemic agents | MERCK & CO., INC. (US) | 1990-12-25 | — | — | US | disclosed |
| EP-0330263-A1 | Piperazinylalkylpyrimidines as hypoglycemic agents | MERCK & CO. INC. (US) | 1989-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132147-A1 | BAX INHIBITORS AND USES THEREOF | BAX, BCL2, BAK1 | ALDH1A1 4585/4885ALOX15 997/4885TSHR 3456/4885 |
| US-12552790-B2 | Positive modulators of the muscarinic acetylcholine receptor M4 | CHRM4, CHRM1, CHRM5 | ALDH1A1 2392/4885ALOX15 4512/4885TSHR 37/4885 |
| US-20250136600-A1 | POSITIVE MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM4, CHRM1, CHRM3 | ALDH1A1 2993/4885ALOX15 4041/4885TSHR 51/4885 |
| US-20260034127-A1 | TREATMENT OF GVHD | ROCK2, RHOA, MYH2 | ALDH1A1 3146/4885ALOX15 4352/4885TSHR 4630/4885 |
| US-12344608-B2 | Positive modulators of the muscarinic acetylcholine receptor M4 | CHRM4, CHRM1, CHRM3 | ALDH1A1 2993/4885ALOX15 4041/4885TSHR 51/4885 |
| US-20250122198-A1 | POSITIVE MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM4, CHRM1, CHRM3 | ALDH1A1 2993/4885ALOX15 4041/4885TSHR 51/4885 |
| US-12479857-B2 | Bax inhibitors and uses thereof | BAX, TMBIM6, BCL2 | ALDH1A1 4296/4885ALOX15 2696/4885TSHR 4763/4885 |
| US-20260035366-A1 | POSITIVE MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM4, CHRM3, CHRM5 | ALDH1A1 3334/4885ALOX15 3943/4885TSHR 67/4885 |
| US-20250230155-A1 | 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | CHRM5, CHRM4, CHRM1 | ALDH1A1 1671/4885ALOX15 4659/4885TSHR 123/4885 |
| US-12448380-B2 | Positive modulators of the muscarinic acetylcholine receptor M4 | CHRM4, CHRM1, CHRM3 | ALDH1A1 2993/4885ALOX15 4041/4885TSHR 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.